Cite
HARVARD Citation
Taiwo, B. et al. (2018). ACTG A5353: A Pilot Study of Dolutegravir Plus Lamivudine for Initial Treatment of Human Immunodeficiency Virus-1 (HIV-1)–infected Participants With HIV-1 RNA <500000 Copies/mL. Clinical infectious diseases. pp. 1689-1697. [Online].